PREDNISOLONE SODIUM PHOSPHATE- prednisolone tablet, orally disintegrating United States - English - NLM (National Library of Medicine)

prednisolone sodium phosphate- prednisolone tablet, orally disintegrating

mylan pharmaceuticals inc. - prednisolone sodium phosphate (unii: iv021nxa9j) (prednisolone - unii:9phq9y1olm) - prednisolone 21-phosphate 10 mg - prednisolone sodium phosphate orally disintegrating tablets are indicated in the treatment of the following diseases or conditions: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: during acute episodes in: for the treatment of: to induce a diuresis or remission of proteinuria in nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus as adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: during an exacerbation or as maintenance therapy in selected cases of: prednisolone sodium phosphate orally disintegrating tablets are contraindicated in patients who are hypersensitive to corticosteroids such as prednisolone or any components of this product. rare instances of anaphylactoid reactions have occurred in patients receiving corticosteroid therapy. based on findings from human and animal studies, corticosteroids